229 related articles for article (PubMed ID: 24392841)
1. The role of drug metabolizing enzymes in clearance.
Di L
Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):379-93. PubMed ID: 24392841
[TBL] [Abstract][Full Text] [Related]
2. Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes.
Zientek MA; Youdim K
Drug Metab Dispos; 2015 Jan; 43(1):163-81. PubMed ID: 25297949
[TBL] [Abstract][Full Text] [Related]
3. Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.
Argikar UA; Potter PM; Hutzler JM; Marathe PH
AAPS J; 2016 Nov; 18(6):1391-1405. PubMed ID: 27495117
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Differential Tissue Abundance of Major Non-CYP Enzymes in Human.
Basit A; Neradugomma NK; Wolford C; Fan PW; Murray B; Takahashi RH; Khojasteh SC; Smith BJ; Heyward S; Totah RA; Kelly EJ; Prasad B
Mol Pharm; 2020 Nov; 17(11):4114-4124. PubMed ID: 32955894
[TBL] [Abstract][Full Text] [Related]
5. Comparative gene expression of intestinal metabolizing enzymes.
Shin HC; Kim HR; Cho HJ; Yi H; Cho SM; Lee DG; Abd El-Aty AM; Kim JS; Sun D; Amidon GL
Biopharm Drug Dispos; 2009 Nov; 30(8):411-21. PubMed ID: 19746353
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Prediction of Human Hepatic Clearance for P450 and Non-P450 Substrates from In Vivo Monkey Pharmacokinetics Study and In Vitro Metabolic Stability Tests Using Hepatocytes.
Nishimuta H; Watanabe T; Bando K
AAPS J; 2019 Jan; 21(2):20. PubMed ID: 30673906
[TBL] [Abstract][Full Text] [Related]
7. Strategies for a comprehensive understanding of metabolism by aldehyde oxidase.
Hutzler JM; Obach RS; Dalvie D; Zientek MA
Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):153-68. PubMed ID: 23231678
[TBL] [Abstract][Full Text] [Related]
8. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.
Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A
Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476
[TBL] [Abstract][Full Text] [Related]
9. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.
Miners JO; Mackenzie PI; Knights KM
Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925
[TBL] [Abstract][Full Text] [Related]
10. The use of hepatocytes to investigate UDP-glucuronosyltransferases and sulfotransferases.
Fournel-Gigleux S; Coughtrie MW; Ouzzine M; Magdalou J
Methods Mol Biol; 2010; 640():309-26. PubMed ID: 20645060
[TBL] [Abstract][Full Text] [Related]
11. In vitro interaction of a novel neutrophil growth factor with human liver microsomal cytochromes P450 and the contribution of UDP-glucuronosyltransferases to its metabolism.
Siller M; Anzenbacher P; Anzenbacherová E; Doležal K; Strnad M
Xenobiotica; 2011 Nov; 41(11):934-44. PubMed ID: 21745145
[TBL] [Abstract][Full Text] [Related]
12. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
[TBL] [Abstract][Full Text] [Related]
13. Toward an integrated human clearance prediction strategy that minimizes animal use.
Beaumont K; Gardner I; Chapman K; Hall M; Rowland M
J Pharm Sci; 2011 Oct; 100(10):4518-35. PubMed ID: 21710508
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism.
Zhang D; Zhang D; Cui D; Gambardella J; Ma L; Barros A; Wang L; Fu Y; Rahematpura S; Nielsen J; Donegan M; Zhang H; Humphreys WG
Drug Metab Dispos; 2007 Dec; 35(12):2270-80. PubMed ID: 17898154
[TBL] [Abstract][Full Text] [Related]
15. Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.
Jones CR; Hatley OJ; Ungell AL; Hilgendorf C; Peters SA; Rostami-Hodjegan A
AAPS J; 2016 May; 18(3):589-604. PubMed ID: 26964996
[TBL] [Abstract][Full Text] [Related]
16. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
Cubitt HE; Houston JB; Galetin A
Drug Metab Dispos; 2011 May; 39(5):864-73. PubMed ID: 21303923
[TBL] [Abstract][Full Text] [Related]
17. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450.
Chen Y; Liu L; Nguyen K; Fretland AJ
Drug Metab Dispos; 2011 Mar; 39(3):373-82. PubMed ID: 21148079
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Drug Metabolism Using Liver Microsomes.
Knights KM; Stresser DM; Miners JO; Crespi CL
Curr Protoc Pharmacol; 2016 Sep; 74():7.8.1-7.8.24. PubMed ID: 27636111
[TBL] [Abstract][Full Text] [Related]
19. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
[TBL] [Abstract][Full Text] [Related]
20. Modulation of metabolizing enzymes by bisphenol a in human and animal models.
Quesnot N; Bucher S; Fromenty B; Robin MA
Chem Res Toxicol; 2014 Sep; 27(9):1463-73. PubMed ID: 25142872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
